[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse KANSL1

Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus. Chromosome, centromere, kinetochore
Domain PF15275 PEHE domain
Function

As part of the NSL complex it is involved in acetylation of nucleosomal histone H4 on several lysine residues and therefore may be involved in the regulation of transcription.

> Gene Ontology
 
Biological Process GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0043543 protein acylation
GO:0043967 histone H4 acetylation
GO:0043981 histone H4-K5 acetylation
GO:0043982 histone H4-K8 acetylation
GO:0043984 histone H4-K16 acetylation
Molecular Function GO:0001047 core promoter binding
GO:0004402 histone acetyltransferase activity
GO:0008080 N-acetyltransferase activity
GO:0010485 H4 histone acetyltransferase activity
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0034212 peptide N-acetyltransferase activity
GO:0035035 histone acetyltransferase binding
GO:0043995 histone acetyltransferase activity (H4-K5 specific)
GO:0043996 histone acetyltransferase activity (H4-K8 specific)
GO:0046972 histone acetyltransferase activity (H4-K16 specific)
GO:0061733 peptide-lysine-N-acetyltransferase activity
Cellular Component GO:0000123 histone acetyltransferase complex
GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0031248 protein acetyltransferase complex
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0044545 NSL complex
GO:0044665 MLL1/2 complex
GO:0071339 MLL1 complex
GO:0098687 chromosomal region
GO:1902493 acetyltransferase complex
GO:1902562 H4 histone acetyltransferase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214847: HATs acetylate histones
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KANSL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KANSL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.56 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KANSL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2150.298
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1690.764
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2520.533
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3560.342
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.030.99
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7750.807
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1690.624
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3480.828
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0380.983
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1160.93
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9750.594
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0150.816
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KANSL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KANSL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KANSL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KANSL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KANSL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KANSL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KANSL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKANSL1
NameKAT8 regulatory NSL complex subunit 1
Aliases DKFZP727C091; MSL1v1; CENP-36; centromere protein 36; KIAA1267; KDVS; hMSL1v1; MLL1/MLL complex subunit KANS ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KANSL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.